Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5

Documents similaires

• Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials
  par: Peter Rossing, et autres
  Publié: (2025)
• Pharmacological characteristics of once‐weekly insulin icodec in Japanese individuals with type 1 diabetes
  par: Takashi Eto, et autres
  Publié: (2024)
• Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c , BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1–5
  par: Alice Y. Y. Cheng, et autres
  Publié: (2025)
• Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the ONWARDS 1–5 trials
  par: Harpreet S. Bajaj, et autres
  Publié: (2024)
• Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
  par: Xichen Tong, et autres
  Publié: (2026)